Skip to main content

Table 2 Balance of covariates before and after matching

From: Can levosimendan reduce ECMO weaning failure in cardiogenic shock?: a cohort study with propensity score analysis

  Unmatched* Matched
Levosimendan (n = 48) Control (n = 128) p Levosimendan (n = 48) Control (n = 78) p
Variable (mean)
 Age (years) 53.9 52.6 0.575 54.3 54.7 0.866
 Male (%) 62 65 0.692 0.62 0.65 0.785
 Potential for recovery 2.32 2.12 0.104 2.31 2.35 0.747
 SAPS-II 53.5 51.7 0.424 52.7 52.1 0.824
 SOFA 11.5 11.8 0.530 11.3 11.5 0.687
 LVEF (%) 18 20.2 0.241 18 17 0.690
 VA-ECMO duration (days) 10.6 6.5 <0.001 10.8 10.2 0.478
 Serum lactate level (mmol/L) 6.4 7.5 0.178 6.3 6.1 0.816
  1. Myocardial recovery potential: High 1 intermediate 2, Low 3 SAPS-II simplified acute physiology score, SOFA sequential organ failure assessment, LVEF left ventricular ejection fraction. Data are expressed as mean. The p value refers to a comparison between the levosimendan group and the control group. *Compared to the entire cohort (n = 200), the unmatched population had 176 patients since there were 24 patients with missing data on some of the variables used in the analysis